Replies to post #521338 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Exactly....

Why go through a Rube Goldberg process to find a bunch of proteins, make an mRNA sequence for each, then shoot that into a patient and hope it finds DCs in your body, hope those DCs take up the mRNA and transcribe it into the same proteins you already have, present them on their surface, and hope T cells are recruited?

And why do all of this when you already have Keytruda showing that in combo with DCVax the two fight GBM better than either alone? Well, maybe when you try to bullshit a woman like LP into selling or partnering on the cheap?

[biosectinvestor]

Agreed. It is engineered and artificial. It’s not a true cancer platform, it’s a complexly engineered vaccine platform that needs to be re-engineered for each cancer type. It’s not natural. And there is no guarantee that it will be specific to individual cancers.

[Know-Fear]

Diver, Agreed. The effort to expand mRNA vaccines into the oncology arena seems to be encountering some headwinds.

[Doc logic]

iwasadiver,

When NWBO first began to challenge big pharma by seeking a combo patent for checkpoint inhibitors the attacks on NWBO began to intensify. It was 2014 when they first started looking for ways to mass produce L as well with a closed system process. Big pharma knew developing this would be difficult and manual process costly so they did not take NWBO too seriously. They were willing to let others swat them away like a pesky fly instead of see them as a legit business worth valuing according to their potential. Now they realize their very costly mistake and tried the failing mRNA end around approach but are making huge piles of money with their checkpoint inhibitors. Because of this they don’t want the value of those products to diminish any sooner than absolutely necessary by alerting the world to what NWBO has, especially improved Direct.
Big pharmas are not the only ones with money and experienced leadership talent will switch sides when the opportunity presents itself. Young talent will seek to join a company that represents the future instead of the past. Transformation can happen quickly because of all the great connections NWBO has with top tier researchers and business talent. For example, Roger Perlmutter likely has seen the writing on the wall for quite some time and any retirement announcement from his now non executive role at Merck might be the start of something new for him. His background includes immunology and he was executive BP head of research at Merck. If I were him I would be begging to join in the early stage planning for further development of product usage for DCVax. Best wishes.